A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines

BACKGROUND: Immunogenicity of inactivated SARS-CoV-2 vaccine has waning antibody over time. With the emergence of the SARS-CoV-2 delta variant, which requires higher neutralizing antibody to prevent infection, a booster dose is needed. OBJECTIVE: To evaluate immunogenicity and reactogenicity of stan...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanthapisal, Sira, Puthanakit, Thanyawee, Jaru-Ampornpan, Peera, Nantanee, Rapisa, Sodsai, Pimpayao, Himananto, Orawan, Sophonphan, Jiratchaya, Suchartlikitwong, Pintip, Hiransuthikul, Narin, Angkasekwinai, Pornpimon, Tangsathapornpong, Auchara, Hirankarn, Nattiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947780/
https://www.ncbi.nlm.nih.gov/pubmed/35341647
http://dx.doi.org/10.1016/j.vaccine.2022.03.036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947780/
https://www.ncbi.nlm.nih.gov/pubmed/35341647
http://dx.doi.org/10.1016/j.vaccine.2022.03.036

Ejemplares similares